CRBN and idiopathic pulmonary fibrosis: A computational investigation of a well-known AMPK activator DHFO, having structural features that are slightly different from thalidomide was reported to have better CRBN binding affinity than thalidomide (Nayek et al. 2022), Thus, the activation of the AMPK signalling pathway is crucial for protecting against IPF.